$SRNE The reason Sorrento's stock popped up in 2015 is the 1.3 Billion Cynviloq cancer drug deal but Ji was robbed. Cynviloq was a generic version of a prominent cancer drug and it was acquired by NantPharma, but they paid Sorrento 90 million up front and the rest pending FDA approvals etc. After NantPharma paid the 90 million they killed the drug. Here is the lawsuit. News story: biospace.com/article/-b-pat... Recent update: investors.sorrentotherapeut...
  • 12